DOXIMITY INC

Business Model and Scope

Doximity operates a U.S. professional network and workflow platform for physicians and other medical professionals. More than three million members were registered at March 31, 2026, including over 85% of U.S. physicians, two-thirds of nurse practitioners and physician assistants, and about 90% of graduating U.S. medical students. Members use news, professional profiles, networking, telehealth, fax, secure messaging, on-call scheduling, drug reference, clinical AI and documentation tools without paying for the core platform.

Revenue comes from organizations seeking access to or productivity among this professional audience. Marketing Solutions lets pharmaceutical manufacturers and health systems deliver sponsored content to selected specialties, credentials and locations. Hiring Solutions sells recruiting access and includes Curative Talent's staffing service. Workflow Solutions sells enterprise use of communication, scheduling and AI tools to health systems and other health-care organizations. Approximately 94% of fiscal 2026 revenue came from subscription customers.

The economic model is therefore not a paid social network for doctors. It is a two-sided professional platform: free utility and verified identity attract and engage clinicians; pharmaceutical and health-system customers pay for targeted communication, recruiting and workflow. This distinction matters because member adoption creates the inventory, but customer budgets create revenue.

Customers and Purchasing Decisions

Medical professionals need credible information, secure communication and less administrative work. They can use email, electronic health records, journals, search engines, general social networks, hospital systems and specialist applications instead. Doximity earns attention when a tool saves time inside a clinical workflow and when the network contains relevant, verified peers. Registration alone has little economic value if clinicians do not return or trust sponsored and AI-generated content.

Pharmaceutical customers buy access to precisely defined clinician audiences and measurable engagement for individual brands. Their alternative is medical websites, journals, conferences, field sales, agencies and emerging clinical-information platforms. Health systems buy recruitment efficiency, service-line marketing, telehealth, scheduling, communication and AI productivity. They can use general software, build internally, buy point solutions or rely on staffing firms. Procurement, privacy review and integration give large customers bargaining power.

Customer concentration is material. One customer accounted for at least 10% of fiscal 2026 revenue, and management states that a relatively small number of key customers contribute a concentrated share. Agencies intermediate some spending and can aggregate bargaining power. Pharmaceutical brand cycles, regulatory approvals, patent expirations and marketing policy can change a program quickly. The member network may be broad while the paying-customer base remains narrow.

Profit Creation and Value Capture

Doximity creates profit by providing free, low-marginal-cost digital tools that concentrate verified clinician attention, then selling subscription modules and enterprise workflow to organizations that value precise reach or productivity. A Marketing Solutions subscription can be expanded by adding brands, service lines, modules or target groups without proportionate hosting cost. Hiring and workflow products monetize the same identity, data and engagement layer. This produces high gross margin when customer revenue grows faster than hosting, support and content cost.

Revenue increased from $343.5 million in fiscal 2022 to $419.1 million in 2023, $475.4 million in 2024, $570.4 million in 2025 and $644.9 million in 2026. Fiscal 2026 gross profit was $574.5 million, an 89% margin. Operating income was $214.9 million and operating cash flow $326.5 million. Capital intensity is low because the product is software; the main reinvestment is engineering, data, AI infrastructure, sales and clinical expertise rather than factories or inventory.

The latest year also exposes limits. Revenue grew 13%, down from 20% in 2025. Net revenue retention fell to 109% from 119%, meaning expansion still exceeded contraction and churn but at a much narrower rate. Operating income declined from $227.8 million despite revenue growth because R&D rose 40%, including substantial stock compensation, and AI-related hosting and amortization increased. Quarterly active providers using workflow tools grew to 0.81 million from 0.62 million, supportive engagement evidence, but it has not yet produced proportional operating leverage.

Physicians capture free productivity tools and information. Pharmaceutical firms and health systems retain the economic return from better marketing, recruiting and workflow. Employees captured $121.6 million of stock-based compensation in fiscal 2026, versus $196.1 million of net income. Cloud, data and software suppliers gain from hosting and AI usage. Agencies mediate customer budgets. Common owners receive the residual only after dilution, acquisitions and repurchases. High gross margin is a starting condition, not the final distribution of value.

Industry Structure and Capital Cycle

Doximity competes for members with LinkedIn, Google, Meta, X and smaller professional networks. In marketing it competes with Medscape, OpenEvidence, other health websites and offline medical promotion. In hiring it faces job boards, self-service tools and national or regional staffing firms. Workflow competitors include Microsoft Teams, Zoom, Teladoc and Amwell for communication and telehealth; QGenda for scheduling; and Abridge, OpenAI, Anthropic and other AI providers for clinical productivity.

Customers have meaningful power because pharmaceutical and health-system budgets are concentrated and programs are periodically renegotiated. Members pay nothing and can use several tools simultaneously, so their switching cost is attention and workflow habit rather than price. Suppliers include public identity and licensing data, medical publishers, cloud providers, AI models, communication carriers and skilled engineers. Doximity combines public and proprietary data, but source restrictions or infrastructure pricing can shift economics to suppliers.

Entry barriers are uneven. A new AI assistant or telehealth feature can be launched quickly; building a verified network spanning most U.S. physicians, gaining clinical trust and selling into regulated enterprises takes longer. General technology firms have capital and distribution but may lack medical identity and workflow depth. Specialist vendors can win one function without replicating the network. Interoperability with hospital systems can make a point solution more useful than a broad standalone platform.

The capital cycle uses software development and commercial spending, not physical capacity. High margins attract venture funding, large-language-model providers and incumbent health IT vendors. Competitors can subsidize clinical tools to sell cloud consumption, EHR modules or other services. Pharmaceutical promotional budgets also follow drug launches and regulation, while health-system IT budgets follow margins and consolidation. When many vendors chase the same budget, customer acquisition cost, free features and compensation rise before reported revenue slows. Doximity's defense must be superior return for customers and embedded clinician usage, not merely a large addressable market.

Sources and Durability of Competitive Advantage

Doximity's plausible advantage is the interaction of verified professional identity, broad physician coverage, specialty and career data, free workflow utility, customer targeting and accumulated engagement signals. A customer can address a defined group without rebuilding the identity graph. A clinician finds more relevant peers and tools where colleagues already participate. Residency Navigator brings medical students into the network early, while workflow products create recurring reasons to return.

This is a network effect only where additional active, verified members improve utility or targeting. Three million registrations do not by themselves prove daily engagement, pricing power or customer return. Doximity's reported 0.81 million quarterly active workflow providers is more economically informative than total profiles but still excludes reading and other uses and does not measure depth. The company must protect the boundary between useful clinical content and promotion; loss of physician trust would reduce both sides simultaneously.

The data and clinical workflow system is difficult to reproduce quickly, but competitors can attack modules. AI lowers the cost of content retrieval and drafting; EHR vendors control the primary clinical record; large platforms can bundle communication. Evidence supporting durability would include stable active usage, customer renewal, cross-module expansion and pricing based on measured outcomes. Contrary evidence would be further NRR decline, a large-customer loss, lower clinician engagement or AI tools shifting attention outside the platform.

Operating System and Strategic Trade-offs

Doximity pre-populates and verifies professional profiles, aggregates public and member-supplied information, personalizes content, builds workflow tools and sells targeted programs. Small distributed product teams combine engineers, data scientists, clinical editors and member feedback. Customer teams configure marketing modules or enterprise products; usage and campaign data inform subsequent product and sales decisions.

Free tools are not charity; they are supply acquisition and retention for the commercial network. Dialer, fax, messaging, Amion scheduling, Ask and Scribe place Doximity closer to routine work than a newsfeed alone. That can lower member acquisition cost and improve targeting data. It also increases hosting, clinical-safety, support and compliance requirements. Ask includes drug references and physician review through PeerCheck, while Scribe generates clinical documentation; errors have higher consequences than ordinary consumer software mistakes.

The operating trade-off is trust versus monetization. More sponsored content can raise short-term revenue but reduce professional engagement. More AI automation can improve utility but introduce hallucination, attribution and liability risk. Curative Talent adds a labor-intensive staffing model to an otherwise high-margin software platform, while acquisitions such as AMiON and Pathway expand workflow but require integration. Useful measures are active workflow providers, customer NRR, subscription mix, average revenue per customer, hosting cost, renewal, AI usage and safety events—not registered membership alone.

Financial Resilience

At March 31, 2026, Doximity held $219.2 million of cash and $529.4 million of marketable securities. Total liabilities were $172.9 million, mostly current operating liabilities and deferred revenue; the balance sheet reported no borrowings. Operating cash flow of $326.5 million materially exceeded capital requirements. This is a strong capacity to continue product investment through a customer-budget slowdown without external finance.

Asset quality is generally high: liquid securities dominate, and receivables were $144.8 million. Goodwill and intangibles totaled about $120 million following acquisitions and could be impaired if products underperform, but they are modest relative to liquidity. Deferred revenue provides cash before service and is an operating obligation rather than debt. Customer concentration is the main financial sensitivity because one lost pharmaceutical program could affect revenue faster than costs adjust.

An adverse case combines delayed drug launches, pharmaceutical budget cuts, hospital financial stress, loss of a key customer, a privacy incident and heavier AI infrastructure expense. Revenue slows while engineers, clinical validation and compliance remain necessary. Doximity could absorb this without refinancing, but margins and cash would decline. Financial resilience is high; the more relevant risk is management consuming excess liquidity on repurchases or acquisitions before the platform's AI economics are proven.

Capital Allocation and Shareholder Outcomes

Internal product investment is justified when it deepens recurring workflow and strengthens customer outcomes without compromising trust. R&D rose to $130.7 million in fiscal 2026, partly for AI. The hurdle should include clinical accuracy, adoption and incremental customer revenue, not feature release. Pathway Medical was acquired for $36.3 million to add clinical decision technology; Curative and AMiON extended staffing and scheduling. Each acquisition should be judged on retained users and incremental cash, not strategic vocabulary.

Doximity completed a $500 million Class A repurchase program by March 2026 and authorized another $500 million. Shares outstanding declined to 183.1 million from 188.9 million year over year. Repurchases can offset dilution, but fiscal 2026 stock-based compensation was $121.6 million and remains a large economic cost. Net share reduction and per-share cash generation, after compensation, are the relevant tests.

Governance affects who controls allocation. Class B shares carry ten votes each, and executive officers, directors and affiliates held about 79% of voting power at year-end. Public Class A owners have limited influence over acquisitions, compensation and repurchases. The debt-free balance sheet protects them financially, but concentrated control means outcomes depend heavily on the controller's discipline.

Legal and Regulatory Exposure

Doximity handles clinician identity, professional and patient communication, and health-related data. It is subject to HIPAA, state privacy and medical laws, breach-notification rules, consumer and financial-service provisions, advertising standards and contractual health-system requirements. Noncompliance can produce fines, operating restrictions, customer termination, provider-license consequences and reputational damage. A breach or misuse of targeting data would directly weaken member trust.

Clinical AI raises more consequential exposure. Ask, PeerCheck and Scribe can influence information retrieval and documentation. Inaccurate, biased or insufficiently attributed output may contribute to clinical error even when Doximity disclaims medical decision-making. New AI rules could require validation, disclosure, monitoring or changes to training data. Marketing content is also regulated: sponsored pharmaceutical communication must remain distinguishable from independent clinical information.

Intellectual-property and content licenses, telehealth rules, prescription functionality, recruiting law and state-by-state health regulation add complexity. Regulation can protect Doximity by raising the cost of trusted entry, but a failure can erase that trust quickly. The filing does not identify a single proceeding that threatens viability; the economic exposure is cumulative and tied to the platform's permission to handle sensitive workflows.

Conclusion, Uncertainties and Disconfirming Evidence

Doximity creates value by making a verified medical-professional network useful enough that clinicians contribute attention and workflow, then selling targeted access and enterprise productivity to pharmaceutical manufacturers and health systems. Broad physician coverage, professional identity, proprietary engagement data and workflow tools plausibly reduce customer search cost and create a defensible distribution channel. High gross margin, strong cash flow and a debt-free balance sheet support the quality of the current economics.

Contrary evidence tempers that conclusion. Customer concentration persists, fiscal 2026 NRR fell to 109%, operating income declined despite revenue growth, and stock compensation rose sharply. AI both increases product utility and lowers entry barriers for clinical information and documentation. Pharmaceutical and hospital buyers remain powerful, while physicians can multi-home at no monetary cost.

The thesis would be invalidated by sustained NRR below 100%; loss of a major pharmaceutical customer without replacement; declining active workflow use; erosion of physician trust from promotion, privacy or AI error; customer return on marketing weakening; or stock compensation and repurchases failing to improve per-share economics. It would strengthen if active workflow adoption converts into broader subscription expansion, NRR stabilizes, AI costs scale below revenue and customer concentration falls. Doximity's financial structure can withstand adversity; durability depends on preserving the trust mechanism that turns a free professional network into profitable customer access.

Business quality does not by itself establish investment attractiveness; valuation depends on the price paid and the expectations embedded in it.